Selected article for: "case estimate and secondary case"
Author: Jennifer C.E Lane; James Weaver; Kristin Kostka; Talita Duarte-Salles; Maria Tereza F. Abrahao; Heba Alghoul; Osaid Alser; Thamir M Alshammari; Patricia Biedermann; Edward Burn; Paula Casajust; Mitch Conover; Aedin C. Culhane; Alexander Davydov; Scott L. DuVall; Dmitry Dymshyts; Sergio Fernández Bertolín; Kristina Fišter; Jill Hardin; Laura Hester; George Hripcsak; Seamus Kent; Sajan Khosla; Spyros Kolovos; Christophe G. Lambert; Johan ver der Lei; Ajit A. Londhe; Kristine E. Lynch; Rupa Makadia; Andrea V. Margulis; Michael E. Matheny; Paras Mehta; Daniel R. Morales; Henry Morgan-Stewart; Mees Mosseveld; Danielle Newby; Fredrik Nyberg; Anna Ostropolets; Rae Woong Park; Albert Prats-Uribe; Gowtham A. Rao; Christian Reich; Jenna Reps; Peter Rijnbeek; Selva Muthu Kumaran Sathappan; Martijn Schuemie; Sarah Seager; Anthony Sena; Azza Shoaibi; Matthew Spotnitz; Marc A. Suchard; Joel Swerdel; Carmen Olga Torre; David Vizcaya; Haini Wen; Marcel de Wilde; Seng Chan You; Lin Zhang; Oleg Zhuk; Patrick Ryan; Daniel Prieto-Alhambra
Title: Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
  • Document date: 2020_4_10
    • ID: 2hbcbvt6_10
    Snippet: First, new user cohort studies were used to estimate the safety of HCQ compared to sulfasalazine (SSZ), and to assess the risks associated with the addition of AZM compared to amoxicillin (AMX) amongst users of HCQ in patients with rheumatoid arthritis (RA). SSZ and AMX were chosen as active comparators as they have similar indications as the target treatments (HCQ and AZM respectively). As a secondary analysis, self-controlled case series (SCCS).....
    Document: First, new user cohort studies were used to estimate the safety of HCQ compared to sulfasalazine (SSZ), and to assess the risks associated with the addition of AZM compared to amoxicillin (AMX) amongst users of HCQ in patients with rheumatoid arthritis (RA). SSZ and AMX were chosen as active comparators as they have similar indications as the target treatments (HCQ and AZM respectively). As a secondary analysis, self-controlled case series (SCCS) was used to estimate the safety of HCQ in the wider population, including uses for non-RA indications.

    Search related documents:
    Co phrase search for related documents
    • active comparator and HCQ safety: 1
    • active comparator and new user: 1, 2, 3
    • active comparator and new user cohort study: 1, 2
    • active comparator and RA rheumatoid arthritis: 1, 2
    • active comparator and rheumatoid arthritis: 1, 2
    • case series and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • case series and HCQ safety: 1
    • case series and new user: 1, 2
    • case series and new user cohort study: 1
    • case series and RA rheumatoid arthritis: 1, 2, 3, 4, 5
    • case series and rheumatoid arthritis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • case series and SCCS self control case series: 1, 2
    • case series and secondary analysis: 1, 2, 3, 4, 5, 6, 7
    • cohort study and HCQ safety: 1, 2, 3, 4, 5, 6, 7
    • cohort study and new user: 1, 2, 3, 4, 5
    • cohort study and new user cohort study: 1, 2, 3
    • cohort study and RA rheumatoid arthritis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • cohort study and rheumatoid arthritis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cohort study and secondary analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25